Search

Your search keyword '"Merck & Company Inc. -- Management"' showing total 452 results
Start Over Descriptor "Merck & Company Inc. -- Management"
452 results on '"Merck & Company Inc. -- Management"'

151. Company Profile of Calypso Biotech

Subjects
Merck & Company Inc. -- Management, Biotechnology, Biotechnology industries, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

Plan-les-Ouates, Switzerland: Following is the Company Profile of Calypso Biotech: Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck [...]

Published
2017

152. Profile of Eugen Leo Head of Isarna Therapeutics

Subjects
Merck & Company Inc. -- Management, Johnson & Johnson -- Management, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

Munich, Germany : Following is the Profile of Eugen Leo Head of Isarna Therapeutics: Professor Eugen Leo serves as head of clinical development at Isarna Therapeutics. He is a board-certified [...]

Published
2017

153. Profile of David S. Block Director of Cocrystal Pharma

Subjects
Merck & Company Inc. -- Management, E.I. du Pont de Nemours and Co. -- Management, Chemical industry, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

Mountain View: Following is the Profile of David S. Block Director of Cocrystal Pharma: David S. Block has served since 2007 as President and Chief Executive Officer of Gliknik Inc., [...]

Published
2017

154. Profile of Mike Doodson Managing Director of G2B Pharma, Inc

Subjects
Merck & Company Inc. -- Management, Executives, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

Corte Madera, CA: Following is the Profile of Mike Doodson Managing Director of G2B Pharma, Inc: Mike Doodson has over 20 year's experience as a senior operating manager with Merck [...]

Published
2017

155. Profile of Professor William J. Rutter, Ph.D. UCSF, Chiron Founder of Applied BioCode, Inc

Subjects
Merck & Company Inc. -- Management, Hepatitis B vaccines, Hepatitis B, Pharmaceutical industry, Genomics, Biological products industry, Company business management, General interest, News, opinion and commentary
Abstract

Santa Fe Springs, CA: Following is the Profile of Professor William J. Rutter, Ph.D. UCSF, Chiron Founder of Applied BioCode, Inc: In 1981 Dr. Rutter and two colleagues founded Chiron [...]

Published
2017

156. Profile of Roberto Guerciolini, M.D.Senior Vice President of WaVe Life Sciences

Subjects
Merck & Company Inc. -- Management, Vice presidents (Organizations), Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

Cambridge: Following is the Profile of Roberto Guerciolini, M.D.Senior Vice President of WaVe Life Sciences: Dr. Guerciolini has served as a Senior Vice President at WAVE since March 2015. Prior [...]

Published
2017

157. Profile of Fan Fan, PhD Vice President Product Management of DNAnexus

Subjects
Merck & Company Inc. -- Management, Vice presidents (Organizations), Pharmaceutical industry, Product management, Company business management, General interest, News, opinion and commentary
Abstract

Mountain View: Following is the Profile of Fan Fan, PhD Vice President Product Management of DNAnexus: Fan works closely with prospects, customers, and the DNAnexus team to drive product vision [...]

Published
2017

158. Profile of Corinne M. Le Goff Senior Vice President Regional General Manager of Amgen

Subjects
Merck & Company Inc. -- Management, Vice presidents (Organizations), Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

Woburn, MA: Following is the Profile of Corinne M. Le Goff Senior Vice President Regional General Manager of Amgen: Corinne M. Le Goff joined Amgen in 2015 as senior vice [...]

Published
2017

159. Profile of Peder K. Jensen President of Acorda Therapeutics, Inc

Subjects
Merck & Company Inc. -- Management, Acorda Therapeutics Inc. -- Management, Schering-Plough Corp. -- Management, Pharmaceutical industry, Biological products industry, Consulting services, Company business management, General interest, News, opinion and commentary
Abstract

New York:: Following is the Profile of Peder K. Jensen President of Acorda Therapeutics, Inc.: Peder K. Jensen, M.D., has been a member of Acorda's Board of Directors since April [...]

Published
2017

162. Profile of Director Andy Jorgensen of Mindstream Analytics

Subjects
Merck & Company Inc. -- Management, Verizon Communications Inc. -- Management, JPMorgan Chase & Co. -- Management, AT&T Inc. -- Management, Pfizer Inc. -- Management, Banking industry, Pharmaceutical industry, Telecommunications industry, Telecommunications services industry, Company business management, Banking industry, General interest, News, opinion and commentary
Abstract

Boston: Following is the Profile of Director Andy Jorgensen of Mindstream Analytics: Andy brings more than 25 years of experience in Performance Management and technology solutions. He has led over [...]

Published
2017

163. Profile of Peder K. Jensen, M.D. Board Member of Acorda Therapeutics, Inc

Subjects
Merck & Company Inc. -- Management, Acorda Therapeutics Inc. -- Management, Schering-Plough Corp. -- Management, Pharmaceutical industry, Biological products industry, Consulting services, Company business management, General interest, News, opinion and commentary
Abstract

New York: Following is the Profile of Peder K. Jensen, M.D. Board Member of Acorda Therapeutics, Inc.: Peder K. Jensen, M.D., has been a member of Acorda's Board of Directors [...]

Published
2017

164. Profile of Andy Jorgensen Sr. Partner of Mindstream Analytics

Subjects
Merck & Company Inc. -- Management, Verizon Communications Inc. -- Management, JPMorgan Chase & Co. -- Management, AT&T Inc. -- Management, Pfizer Inc. -- Management, Banking industry, Pharmaceutical industry, Telecommunications industry, Telecommunications services industry, Company business management, Banking industry, General interest, News, opinion and commentary
Abstract

Boston, MA: Following is the Profile of Andy Jorgensen Sr. Partner of Mindstream Analytics: Andy brings more than 25 years of experience in Performance Management and technology solutions. He has [...]

Published
2017

165. DARTMOUTH PROFESSOR GERNGROSS ELECTED TO NATIONAL ACADEMY OF ENGINEERING

Subjects
Merck & Company Inc. -- Management, Entrepreneurship, Pharmaceutical industry, Biological products, Company business management, News, opinion and commentary, National Academy of Engineering -- Management
Abstract

HANOVER, N.H. -- The following information was released by Thayer School of Engineering at Dartmouth: Professor Tillman Gerngross has been elected to The National Academy of Engineering (NAE). Professor Gerngross [...]

Published
2017

166. Profile of Douglas M. Fambrough Chief Executive Officer of Dicerna Pharmaceuticals, Inc

Subjects
Merck & Company Inc. -- Management, Oxford Bioscience Partners -- Management, High technology industry, Chief executive officers, Venture capital companies, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

Cambridge: Following is the Profile of Douglas M. Fambrough Chief Executive Officer of Dicerna Pharmaceuticals, Inc: Douglas M. Fambrough, III Ph.D. co-founded Dicerna in 2007 and has served as the [...]

Published
2017

167. Merck & Company, Inc. (MRK) Position Raised by Violich Capital Management Inc

Subjects
United States. Securities and Exchange Commission -- Management, Merck & Company Inc. -- Management, Pharmaceutical industry, Company business management, Banking, finance and accounting industries
Abstract

Violich Capital Management Inc. increased its position in shares of Merck & Company, Inc. (NYSE:MRK) by 0.5% during the third quarter, according to its most recent disclosure with the Securities [...]

Published
2017

168. Merck is showing its age

Author

Weber, Joseph

Subjects
Merck & Company Inc. -- Management, Pharmaceutical industry -- Management
Published
1993

169. Drugs I

Subjects
Merck & Company Inc. -- Management, Schering-Plough Corp. -- Management, SmithKline Beecham PLC -- Management, Wall Street Transcript (Periodical) -- Achievements and awards, Pharmaceutical industry -- Management, Banking, finance and accounting industries, Business
Published
1993

170. Bayer AG Meet Management in London - Final

Subjects
Merck & Company Inc. -- Management, Pharmaceutical industry, Company business management, Business
Abstract

Presentation ALEXANDER ROSAR, IR, BAYER AG: So, ladies and gentlemen, good morning. Welcome, also, on behalf of the entire Bayer management team. We are happy that so many of you [...]

Published
2014

171. Bayer AG Meet Management in New York - Final

Subjects
Merck & Company Inc. -- Management, Bayer AG -- Management, Pharmaceutical industry, Company business management, Business
Abstract

Presentation ALEXANDER ROSAR, HEAD - IR, BAYER AG LEVERKUSEN: So, good morning, everybody. I'd like to welcome also on behalf of the entire management team to our meanwhile third meet [...]

Published
2014

172. Merck's Many IT Challenges

Author

Conry-Murray, Andrew

Subjects
Merck & Company Inc. -- Management, Pharmaceutical industry -- Management, Company business management, Business, Computers, High technology industry
Abstract

Developing apps isn't all Merck CIO and executive VP of global services J. Chris Scalet is up to. In March 2009, the drugmaker announced it was acquiring rival Schering-Plough for [...]

Published
2010

173. Biond Biologics Closes on $17 Million in Series B Financing

Subjects
Merck & Company Inc. -- Management, Pharmaceutical industry, Company business management, Business, Business, international, Telecommunications industry
Abstract

Biond Biologics reported the closing of a $17 million Series B financing.According to a media release, Biond was founded in 2016 by the former scientific team of cCam Biotherapeutics, an [...]

Published
2019

174. Drug industry

Subjects
Merck & Company Inc. -- Management, Bristol-Myers Squibb Co. -- Management, Warner-Lambert Co. -- Management, Wall Street Transcript (Periodical) -- Achievements and awards, Pharmaceutical industry -- Management, Banking, finance and accounting industries, Business
Published
1991

175. Invasive vs Conservative Management Strategy for ACS

Subjects
Merck & Company Inc. -- Management, Pfizer Inc. -- Management, Pharmaceutical industry, Flexible response (Strategy), Combat survivability (Military engineering), Strategic planning (Business), Deterrence (Strategy), Company business management, Health
Abstract

Invasive vs Conservative Management Strategy for ACS Abstract & Commentary By Jonathan Abrams, MD Professor of Medicine, Division of Cardiology, University of New Mexico, Albuquerque Dr. Abrams serves on the [...]

Published
2008

176. Glaxo Mimics Carmaker to Speed Vaccine; Using the 'one roof' management technique developed by Renault, the British pharma rushed its HPV vaccine to close the gap with rival Merck

Subjects
Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Methods, Transportation equipment industry -- Company sales and earnings, Transportation equipment industry -- Methods, Vaccines -- Methods, Biological products industry -- Company sales and earnings, Biological products industry -- Methods, Papillomavirus infections -- Methods, Company business management, Company earnings/profit, Merck & Company Inc. -- Company sales and earnings, Merck & Company Inc. -- Management, Renault S.A. -- Company sales and earnings, Renault S.A. -- Management
Published
2007

177. Glaxo Mimics Carmaker to Speed Vaccine; Using the 'one roof' management technique developed by Renault, the British pharma rushed its HPV vaccine to close the gap with rival Merck

Subjects
Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Methods, Transportation equipment industry -- Company sales and earnings, Transportation equipment industry -- Methods, Vaccines -- Methods, Biological products industry -- Company sales and earnings, Biological products industry -- Methods, Papillomavirus infections -- Methods, Company business management, Company earnings/profit, Merck & Company Inc. -- Company sales and earnings, Merck & Company Inc. -- Management, Renault S.A. -- Company sales and earnings, Renault S.A. -- Management
Published
2007

179. Taking Their Medicine

Author

Herper, Matthew

Subjects
Pharmaceutical industry -- Officials and employees, Pharmaceutical industry -- Management, Company business management, Merck & Company Inc. -- Management, Merck & Company Inc. -- Officials and employees
Published
2007

180. Drug Stocks Could Regain Their Health

Author

Rayasam, Renuka

Subjects
Pharmaceutical industry -- Securities, Pharmaceutical industry -- Intellectual property, Pharmaceutical industry -- Product information, Pharmaceutical industry -- Management, Biotechnology industry -- Securities, Stocks -- Prices and rates, Stocks -- Forecasts and trends, Investment analysis, Company business management, Company securities, Market trend/market analysis, Merck & Company Inc. -- Product information, Merck & Company Inc. -- Intellectual property, Merck & Company Inc. -- Management, Pfizer Inc. -- Securities, Pfizer Inc. -- Product information, Pfizer Inc. -- Intellectual property, Pfizer Inc. -- Management
Published
2007

182. Merck named and shamed for guideline breach

Subjects
Merck & Company Inc. -- Management, Pharmaceutical industry -- Management, Pharmacists -- Services, Teaching -- Equipment and supplies, Teaching -- Usage, Company business management, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries
Abstract

Industry Panel decides that Chinese meal was not an educational programme The UK wing of drugmaker Merck has been reprimanded for breaching industry ethical guidelines by entertaining a group of [...]

Published
2006

183. Merck reprieved in Vioxx battle

Subjects
Merck & Company Inc. -- Management, Pharmaceutical industry -- Management, Heart attack -- Risk factors, Company business management, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries, Vioxx (Medication) -- Usage
Abstract

Medicines `Excessive' compensation claim against Merck overturned by US judge Tom Hawkins Merck has been given a financial reprieve in the legal battle raging over withdrawn painkiller Vioxx after a [...]

Published
2006

184. Merck dealt blows in Vioxx case

Subjects
Merck & Company Inc. -- Management, Pharmaceutical industry -- Management, Analgesics -- Usage, Company business management, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries, Vioxx (Medication) -- Analysis
Abstract

Medicines Firm faces series of compensation claims from US and non-US citizens over effects of painkiller Merck has been dealt a series of blows in the battle to avoid a [...]

Published
2006

185. Is Merck Winning or Losing in the Vioxx Trials?

Author

Simons, John

Subjects
Vioxx (Medication) -- Cases, Pharmaceutical industry -- Management, Pharmaceutical industry -- Cases, Company business management, Company legal issue, Merck & Company Inc. -- Management, Merck & Company Inc. -- Cases
Published
2006

187. Unwelcome suitors; Pharmaceuticals

Subjects
Merck & Company Inc. -- Management, Bayer HealthCare Pharmaceuticals -- Management, Letting of contracts, Pharmaceutical industry -- Management, Company business management, Business, Economics, Business, international
Abstract

Attempts to form a new drugs giant in Germany NATIONAL industrial champions are all the rage in Europe. So when Merck, a middling German drugs and chemicals manufacturer, announced a [...]

Published
2006

188. Early Invasive vs Selectively Invasive Management for Acute Coronary Syndrome

Subjects
Merck & Company Inc. -- Management, Pfizer Inc. -- Management, Pharmaceutical industry, Flexible response (Strategy), Coronary heart disease, Medical research, Medicine, Experimental, Deterrence (Strategy), Company business management, Health
Abstract

Early Invasive vs Selectively Invasive Management for Acute Coronary Syndrome Abstract & Commentary By Jonathan Abrams, MD Dr. Abrams is Professor of Medicine, Division of Cardiology, University of New Mexico, [...]

Published
2005

190. Pfizer and Merck: Different Strokes; Celebrex continues to sell, while Vioxx got yanked. Courts, doctors, patients, and investors will decide which approach is better

Author

Tsao, Amy

Subjects
Vioxx (Medication) -- Product defects and recalls, Celebrex (Medication), Pharmaceutical industry -- Product defects and recalls, Pharmaceutical industry -- Management, Antiarthritic agents -- Adverse and side effects, Antiarthritic agents -- Product defects and recalls, Company business management, Merck & Company Inc. -- Management, Pfizer Inc. -- Management
Published
2004

192. Merck Looks to Big-Time Firms for Vioxx Cases

Author

Henning, Lily

Subjects
Merck & Company Inc. -- Product discontinuation, Merck & Company Inc. -- Cases, Merck & Company Inc. -- Management, Pharmaceutical industry -- Product discontinuation, Pharmaceutical industry -- Cases, Pharmaceutical industry -- Management, Complex litigation -- Management, Company legal issue, Company business management, Business, regional, Law, Vioxx (Medication) -- Cases, Vioxx (Medication) -- Product discontinuation
Published
2004

193. Minimizing the Mess at Merck; The drugmaker needs a new CEO with a battle plan to craft a legal strategy for Vioxx, cut costs, and bolster new products

Author

Barrett, Amy

Subjects
Vioxx (Medication) -- Planning, Vioxx (Medication) -- Management, Vioxx (Medication) -- Product defects and recalls, Pharmaceutical industry -- Cases, Pharmaceutical industry -- Management, Pharmaceutical industry -- Planning, Company business management, Company business planning, Company legal issue, Merck & Company Inc. -- Cases, Merck & Company Inc. -- Management, Merck & Company Inc. -- Planning
Published
2004

194. Merck's Mess

Author

Herper, Matt and Langreth, Robert

Subjects
Vioxx (Medication) -- Health aspects, Vioxx (Medication) -- Adverse and side effects, Vioxx (Medication) -- Cases, Pharmaceutical industry -- Management, Pharmaceutical industry -- Cases, Pharmaceutical industry -- Beliefs, opinions and attitudes, Pharmaceutical industry -- Product information, Company legal issue, Company business management, Merck & Company Inc. -- Management, Merck & Company Inc. -- Cases, Merck & Company Inc. -- Beliefs, opinions and attitudes, Merck & Company Inc. -- Product information
Published
2004

195. KEVIN HOLT, SENIOR PORTFOLIO MANAGER, INVESCO IS INTERVIEWED ON BLOOMBERG TV

Subjects
Merck & Company Inc. -- Management, Bloomberg News -- Management, News agencies, Pharmaceutical industry, Company business management, Law
Abstract

TRANSCRIPT October 02, 2013 NEWS PROGRAM KEVIN HOLT, SENIOR PORTFOLIO MANAGER, INVESCO KEVIN HOLT, SENIOR PORTFOLIO MANAGER, INVESCO IS INTERVIEWED ON BLOOMBERG TV Roll Call, Inc. 1255 22nd Street N.W. [...]

Published
2013

196. Why Merck Missed the Mark; S&P's Herman Saftlas talks about the Street's reaction to the drug giant's disappointing earnings report and what the future may hold

Subjects
Pharmaceutical industry -- Finance, Pharmaceutical industry -- Securities, Pharmaceutical industry -- Officials and employees, Pharmaceutical industry -- Management, Company business management, Company securities, Company earnings/profit, Merck & Company Inc. -- Finance, Merck & Company Inc. -- Securities, Merck & Company Inc. -- Officials and employees, Merck & Company Inc. -- Management
Published
2003

198. Profile of Susmita Sharma Senior Manager of Bridge Partners

Subjects
Merck & Company Inc. -- Management, Qwest Communications International Inc. -- Management, Pharmaceutical industry, Project management, Telecommunications industry, Telecommunications services industry, Company business management, General interest, News, opinion and commentary
Abstract

Seattle: Following is the Profile of Susmita Sharma Senior Manager of Bridge Partners: Susmita brings over 15 years of experience in account management and project management at a wide variety [...]

Published
2017

199. Profile of Peter Loscher CEO of Renova Management AG of Deutsche Bank AG

Subjects
Merck & Company Inc. -- Management, Siemens AG -- Management, General Electric Co. GE Healthcare -- Management, General Electric Co. -- Management, Sanofi India Ltd. -- Management, Banks (Finance), Chairpersons, Chief executive officers, Medical equipment industry, Electronics industry, Pharmaceutical industry, Electric equipment industry, Company business management, Electronics industry, General interest, News, opinion and commentary
Abstract

Hong Kong: Following is the Profile of Peter Loscher CEO of Renova Management AG of Deutsche Bank AG: Career 2014 - 2016 CEO of Renova Management AG 2007 - 2013 [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results